PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on June 26, 2013 under the symbol “ESPR.” In addition, Esperion has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2013. When available, copies of the final prospectus relating to the offering may be obtained by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at batprospectusdept@citi.com, by phone at (800) 831-9146.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.